Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 10Colonic Neoplasms 9Prostatic Neoplasms 8Colorectal Neoplasms 6Neoplasms 5Multiple Myeloma 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Smoldering Multiple Myeloma 3Rectal Neoplasms 3Pancreatic Neoplasms 3Monoclonal Gammopathy of Undetermined Significance 3Lung Neoplasms 3Adenomatous Polyposis Coli 3Uterine Cervical Dysplasia 2Radiodermatitis 2Pain 2Esophageal Neoplasms 2Breast Carcinoma In Situ 2cyclopia sequence 1Uterine Neoplasms 1Tuberous Sclerosis 1Thrombocythemia, Essential 1Stomatitis 1Sezary Syndrome 1Seizures 1Psychological Well-Being 1Prostate Cancer Metastatic Castration Resistant 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 211fludarabine phosphate 185Azacitidine 160fludarabine 144Busulfan 140Tacrolimus 120Mycophenolic Acid 112Cytarabine 111Whole-Body Irradiation 107Peripheral Blood Stem Cell Transplantation 99Antilymphocyte Serum 97Melphalan 91Filgrastim 87Cyclosporine 83Decitabine 82Methotrexate 79venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 47Cord Blood Stem Cell Transplantation 43Clofarabine 42thymoglobulin 41Specimen Handling 35Etoposide 35Methylprednisolone 34Sirolimus 33Biopsy 30Injections 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Curcumin × Clear all
NCT06063486 2026-03-27

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

University of Southern California

Phase 2 Recruiting
30 enrolled
Myeloid

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡